论文部分内容阅读
目的总结分析孟鲁司特钠对支气管哮喘急性发作期患者的治疗效果及其对炎症因子的影响。方法选择2012年6月—2014年6月期间本院收治的90例支气管哮喘患者为研究对象,随机分为观察组和对照组各45例,对照组患者雾化吸入舒利迭治疗,50 mg/250 mg,2次/d,观察组患者给予孟鲁司特钠口服治疗,10 mg/次,1次/d,两组疗程均为2周,观察比较两组患者临床疗效、治疗前后肺功能改善、炎症因子(IL-4、IL-25、IL-33)水平变化情况。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果观察组临床治疗总有效率为88.89%,明显高于对照组的71.11%,对比差异有统计学意义(P<0.05)。观察组治疗后FEV1、FVC、FEV1/FVC分别为(78.4±6.5)%、(66.9±2.6)%、(72.5±6.1),均高于对照组的(70.5±5.2)%、(52.2±5.2)%、(63.5±5.2),对比差异均有统计学意义(均P<0.05)。观察组治疗后的IL-4、IL-25、IL-33炎症因子水平分别为(24.5±2.5)、(133.5±16.5)、(40.2±10.5)ng/L,均低于对照组的(32.5±1.3)、(156.2±16.7)、(53.2±9.8)ng/L,对比差异均有统计学意义(均P<0.05)。结论与舒利迭相比,孟鲁司特钠治疗急性发作期支气管哮喘的临床疗效更佳,更有助于改善患者的肺功能,降低炎症因子水平,值得推广使用。
Objective To summarize the therapeutic effect of montelukast sodium on the patients with acute exacerbation of bronchial asthma and its effect on inflammatory factors. Methods Ninety patients with bronchial asthma admitted to our hospital from June 2012 to June 2014 were randomly divided into observation group (45 cases) and control group (45 cases). Patients in the control group were treated with inhaled seretide (50 mg) / 250 mg, 2 times / d, montelukast sodium oral treatment group, 10 mg / time, 1 / d, the two groups were treated for 2 weeks, the clinical efficacy of two groups were observed and compared before and after treatment of lung Function improvement, inflammatory cytokines (IL-4, IL-25, IL-33) levels. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate of clinical treatment in observation group was 88.89%, which was significantly higher than that in control group (71.11%), the difference was statistically significant (P <0.05). The FEV1, FVC and FEV1 / FVC in the observation group were (78.4 ± 6.5)%, (66.9 ± 2.6)% and (72.5 ± 6.1), respectively, higher than those in the control group (70.5 ± 5.2% and 52.2 ± 5.2 )%, (63.5 ± 5.2), the difference was statistically significant (all P <0.05). The levels of IL-4, IL-25 and IL-33 in the observation group were (24.5 ± 2.5), (133.5 ± 16.5) and (40.2 ± 10.5) ng / L, ± 1.3), (156.2 ± 16.7) and (53.2 ± 9.8) ng / L, respectively (all P <0.05). Conclusion Compared with seretide, montelukast sodium in acute exacerbation of bronchial asthma clinical efficacy is better, but also help to improve patients with pulmonary function, reduce the level of inflammatory cytokines, it is worth promoting the use of.